4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid
• 英文别名: (E)-3-[4-[2-(2,3,4,5,6-pentafluorophenyl)prop-2-enoyl]phenyl]prop-2-enoic acid
• 化学式: C₁₈H₉F₅O₃
• 分子量: 368.26
• InChiKey: GTVSSUKOHOKWKV-QPJJXVBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-[(2,3,4,5,6-pentafluorophenyl)acetyl]cinnamic acid 、 盐酸二甲胺 在 盐酸 、 溶剂黄146 、 paraformaldehyde 作用下， 以 1,4-二氧六环 为溶剂， 以222 mg (93%)的产率得到4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid
  参考文献：
  名称：

  Vinylbenzene derivatives

  摘要：

  本发明提供了以下一般式I及其盐所代表的化合物，这些化合物可用作青光眼的治疗剂， 其中R1为H、较低的烷基或苯基，苯基可由较低的烷基、羟基、较低的烷氧基、卤素、硝基或苯基取代；R2和R3，相同或不同，为H、卤素或较低的烷基；R4和R5，相同或不同，为H、较低的烷基或羧基或其酯；R6为羧基或磷酸酯或其酯。

  公开号：

  US06329547B1

文献信息

• Amide compounds and use thereof
  申请人：——

  公开号：US20030158413A1

  公开（公告）日：2003-08-21

  The present invention relates to an amide compound of the formula 1 wherein R 1 is a hydrogen and the like, R 2 is a hydrogen and the like, X is SO 2 and the like, Y is the formula (III) and the like and a is 2, an isomer thereof or pharmaceutically acceptable salts thereof. The compound of the present invention shows a remarkable and selective Rho kinase inhibitory action, is free of problematic toxicity, shows fine oral absorption and drug kinetics (absorption, distribution, metabolism, excretion and the like of the drug), and shows superior properties (e.g., stability etc.) as a compound. Accordingly, it can be used as a therapeutic drug for various diseases in which Rho kinase is involved.

  本发明涉及一种式1的酰胺化合物，其中R1为氢等，R2为氢等，X为SO2等，Y为式（III）等，a为2，其异构体或其药学上可接受的盐。本发明的化合物显示出显著且选择性的Rho激酶抑制作用，不具有有毒性问题，显示出良好的口服吸收和药物动力学（药物的吸收、分布、代谢、排泄等），并且显示出优越的特性（例如稳定性等）作为一种化合物。因此，它可以作为治疗涉及Rho激酶的各种疾病的治疗药物。
• Preventives/remedies for kidney diseases
  申请人：——

  公开号：US20030096843A1

  公开（公告）日：2003-05-22

  A compound having a Rho kinase inhibitory activity, such as (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)-cyclohexane, has a renal interstitial fibrosis inhibitory action in renal interstitial fibrosis model mice and various other actions, and therefore, is useful as an agent for the prophylaxis or treatment of renal diseases.

  具有Rho激酶抑制活性的化合物，例如（+）-trans-4-(1-氨乙基)-1-(4-吡啶基氨甲酰基)-环己烷，对于肾间质纤维化模型小鼠具有肾间质纤维化抑制作用和其他各种作用，因此，可用作预防或治疗肾脏疾病的药物。
• Antitumor effect potentiators
  申请人：——

  公开号：US20030165576A1

  公开（公告）日：2003-09-04

  When used concurrently with an antitumor agent, a compound having a Rho kinase inhibitory activity, such as (R)-(+)-N-(4-pyridyl)-4-(1-aminoethyl)benzamide, reinforces an antitumor effect of the antitumor agent and is useful as an antitumor effect potentiator. Particularly, a compound having a Rho kinase inhibitory activity used with an antitumor agent in combination can reduce the dose of the antitumor agent, which in turn affords provision of a sufficient effect and/or reduction of side effects.

  当与抗肿瘤药物同时使用时，具有Rho激酶抑制活性的化合物，如(R)-(+)-N-(4-吡啶基)-4-(1-氨乙基)苯甲酰胺，可以增强抗肿瘤药物的抗肿瘤效果，并且可用作抗肿瘤效应增强剂。特别是，与抗肿瘤药物联合使用具有Rho激酶抑制活性的化合物可以降低抗肿瘤药物的剂量，从而提供足够的疗效和/或减少副作用。
• Visual function disorder improving agents
  申请人：——

  公开号：US20040106646A1

  公开（公告）日：2004-06-03

  The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-( 1 H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent has axon of the retinal ganglion cellal extension promoting action and optic nerve cell regeneration promoting action, and is useful for the treatment of a visual function disorder associated with various eye diseases caused by damage, defects, degeneration and the like in the retinal or optic nerve.

  本发明提供了一种含有具有Rho激酶抑制活性的化合物的视觉功能障碍改善剂，特别是(R)-(+)-N-(1H-吡咯[2,3-b]吡啶-4-基)-4-(1-氨基乙基)苯甲酰胺作为有效成分。该剂具有促进视网膜神经节细胞轴突延伸和视神经细胞再生的作用，可用于治疗与视网膜或视神经的损伤、缺陷、退化等引起的各种眼部疾病相关的视觉功能障碍。
• Agent for repairing corneal perception
  申请人：Takayama Yoshiko

  公开号：US20070093513A1

  公开（公告）日：2007-04-26

  The present invention provides a novel pharmaceutical agent for recovering corneal sensitivity after corneal surgery and improving symptoms of dry eye. This pharmaceutical agent is useful for improving decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as post-cataract operation, post-LASIK operation, post-PRK operation, postkeratoplasty operation, neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like, since it contains a Rho protein inhibitor.

  本发明提供了一种新型药物，用于恢复角膜手术后的角膜敏感性，并改善干眼症状。该药物有助于改善与角膜神经退行性疾病相关的降低的角膜敏感性和干眼症，如白内障手术后、激光角膜磨镶术后、表面光学角膜磨镶术后、角膜移植手术后、神经麻痹性角膜病、角膜溃疡、糖尿病性角膜病等，因为它含有Rho蛋白抑制剂。